NKTR

Business Context and Reporting Period

Company: Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2003
Business Overview: Nektar is a drug delivery technology company focusing on pulmonary delivery systems (e.g., Exubera), Advanced PEGylation, and supercritical fluids. The company changed its name in January 2003 to reflect its broadened capabilities. It has been unprofitable since inception and relies heavily on collaborative agreements with pharmaceutical partners, most notably Pfizer Inc.

Key Financial Metrics

Note: Cash and Short-Term Investments calculated as sum of Cash ($21,526) and Short-term investments ($229,986) as of March 31, 2003.

Material Changes vs. Prior Period

• Revenue: Decreased 5% to $25.5 million, primarily due to lower clinical drug and device sales for partnered projects. However, product sales increased 31% to $7.1 million, now representing 28% of total revenue.
• Net Loss: Improved by 20% to $19.9 million, driven by a 23% reduction in Research and Development (R&D) expenses to $32.1 million. This decrease was partly due to the absence of a one-time $5.3 million payment made in Q1 2002 for PulmoSphere technology rights.
• Operating Cash Flow: Deteriorated significantly, with cash used increasing from $19.0 million to $39.9 million. This was driven by a reduction in deferred revenue (timing of partner advances) and payments of accrued liabilities, including $1.4 million in severance from a prior restructuring.
• Interest Income: Decreased by approximately $1.2 million to $1.6 million due to lower investment balances and interest rates.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Management forecasts substantial operating losses to continue for the next few years.
• R&D expenses are expected to remain at current levels or higher in the near term, with a forecasted decrease in internally funded research spending in 3-5 years as projects are partnered or commercialized.
• The company expects sufficient cash to meet operating requirements for at least the next two years.

• Pfizer Dependency: Pfizer accounted for 54% of revenue in Q1 2003. Pfizer indicated it would not file a New Drug Application (NDA) for Exubera (inhaleable insulin) in 2003. Delays or failure to launch Exubera would significantly harm Nektar's financial position.
• Debt Obligations: The company holds approximately $299.2 million in convertible subordinated notes and debentures. Significant maturities are due in 2006 ($7.8M) and 2007 ($291.4M). The company does not expect to satisfy these through operating cash flow and may need to refinance or raise additional capital.
• Legal Proceedings: A lawsuit filed in August 2002 seeking $15 million was settled in April 2003. The settlement was reflected in Q1 2003 results and was deemed not material.
• Regulatory & Commercialization: Success depends on partners obtaining regulatory approval and commercializing products. The company lacks internal capabilities for large-scale clinical studies or marketing.

Investor Verification Checklist

• Exubera Timeline: Verify the current status of Pfizer's NDA filing for Exubera and any updated regulatory timelines, given the 2003 delay announcement.
• Debt Refinancing: Assess the company's strategy for refinancing the $299 million in convertible debt maturing in 2006 and 2007, given the current stock price and market conditions.
• Deferred Revenue: Monitor the timing of partner advance payments, as fluctuations in deferred revenue significantly impact operating cash flow.
• Product Sales Growth: Track the growth of product sales (Advanced PEGylation) to determine if it can offset potential declines in contract research revenue.
• Liquidity Runway: Confirm the burn rate and whether the $251.5 million in cash and investments remains sufficient to fund operations through the projected two-year horizon.